Visual evoked potentials to flash and pattern reversal stimulation after administration of systemic or topical scopolamine

Impaired Visual Inhibition in Amnestic Mild Cognitive Impairment

Objective.The pathophysiology of amnestic mild cognitive impairment (aMCI) and Alzheimer disease (AD) is still a matter of debate. Visual system might be precociously altered, especially for its cholinergic connections. We thus studied patients with aMCI compared to AD with paired-pulse flash-visual evoked potentials (paired-F-VEPs), a putative marker of cholinergic function. Methods. We enrolled 12 adult patients with aMCI and 12 with AD. 14 normal age- and sex-matched subjects acted as controls (HS). Stimuli were single flashes, with interspersed random flash pairs at critical interstimulus intervals (ISIs, 16.5 to 125 ms) with closed eyes. The "single" (unconditioned) F-VEP was split into a "main complex" (50 to 200 ms after the flash) and a "late response" (200 to 400 ms). As for paired stimulation, the "test" F-VEP emerged from electronic subtraction of the "single" F-VEP from the "paired"-F-VEP. Results. In the single F-VEP, P2 latency was prolonged in patients (aMCI and AD) compared to HS (p < .05). As to the paired F-VEPs, in aMCI the "late response" normal inhibition was abolished at ISIs 50-62.5 ms (p ≤ .016), compared to AD and controls. No changes were detected for the "main complex". Conclusions. Paired-F-VEPs demonstrate a defective neural inhibition in the visual system of patients with aMCI at critical intervals. It may represent a compensatory mechanism against neuronal loss, the failure of which may be involved in AD development. Paired-F-VEPs may warrant inclusion in future preclinical/clinical studies, to evaluate its potential role in the pathophysiology and management of aMCI.

Standardization and Validation of the Flash Visual Evoked Potential-P2 Conversion Scores in the Diagnosis of Amnestic Mild Cognitive Impairment and Alzheimer's Dementia

Amnestic mild cognitive impairment (aMCI), which is characterized by normal daily activity, but a significant decline in episodic memory, is now widely accepted as a risk factor for the development of Alzheimer's dementia (AD). Research suggests that many of the same neuropathological changes associated with AD also occur in patients diagnosed with aMCI. A recent review of the literature revealed that the latency of the flash visual-evoked potential-P2 (FVEP-P2) may possess pathognomonic information that may assist in the early detection of aMCI. While standards exist for the recording of FVEP-P2, individual clinics often use recording parameters that may differ, resulting in latencies that may not generalize beyond the clinic that produced them. The present article illustrates the process by which the FVEP-P2 latency can be standardized across clinics using FVEP-P2 Conversion Scores. We then demonstrate the diagnostic accuracy of the newly developed scores. Method: In the present investigation, we used the previously unpublished data containing the FVEP-P2 latencies of 45 AD and 60 controls. Result: We were able to demonstrate the process by which individual clinics may first standardize FVEP-P2 latencies and then examine patient performance using FVEP-P2 Conversion Scores, providing clinicians with a richer context from which to examine the patient performance. Conclusion: Consistent with the findings of previous research, the findings of the present investigation support the use of the FVEP-P2 Conversion Scores in the diagnosis of AD. Future directions, including the modification of recording parameters associated with the FVEP-P2, are also discussed.

The effect of wavelength on the variability of the flash visual evoked potential P2: A potential biomarker for mild cognitive impairment and Alzheimer's dementia

As the number of individuals diagnosed with amnestic mild cognitive impairment (aMCI) and Alzheimer's dementia (AD) increases, a need exists for early detection and treatment of the disorders. A recent review of the literature conducted by Arruda et al. (2020) revealed that the latency of the flash visual-evoked potential-P2 (FVEP-P2) may possess pathognomic information that may assist in the early detection and treatment of each disease. Unfortunately, while group differences in latency are robust, the ability to discriminate between individuals remains difficult due to the natural variability associated with the FVEP-P2 latency. In the current investigation, we examine the role of wavelength of light in the production of the FVEP-P2, with the goal of reducing the variability associated with the FVEP-P2 latency and improving the diagnostic accuracy of the FVEP-P2 evaluation.

METHOD

Twenty-four healthy individuals (11 males and 13 females), ages 18 to 36 years (M = 25.00, SD = 5.60), participated in this investigation. Each participant experienced five blocks of 100 strobe flashes (or trials) under two different light conditions (blue filtered light and polychromatic white light) with their eyes closed. The FVEP-P2 associated with each trial was identified and the latency and amplitude of each component was calculated.

RESULT

The results of several repeated measures analysis of variance revealed no statistically significant differences in intra- and inter-individual variability associated with the P2 latency or amplitude. However, there was a significant difference in the amplitude of the P2 produced by the two lights, with blue filtered light producing significantly lower amplitudes than the polychromatic white light.

CONCLUSION

The results of the present investigation suggest that while imperfect, the current practice of employing polychromatic white light in the production of the FVEP-P2 remains the gold standard and that additional methods of reducing the natural variability of the P2 need to be developed if the FVEP-P2 latency is to be used as a biomarker.

The flash visual evoked potential-P2 and the detection of amnestic mild cognitive impairment: A review of empirical literature

Amnestic Mild Cognitive Impairment (aMCI) is now recognized as an early risk state for the development of Alzheimer's dementia (AD). Biomarkers, including those that are cerebrospinal fluid or brain imaging based, have yet to provide the ultimate marker variable. A need currently exists for a non-invasive, easy to administer biomarker that contains aMCI/AD specific pathognomic information.

OBJECTIVE

The objective of the present investigation was to provide an updated review of the Flash Visual Evoked Potential-P2 (FVEP-P2) as a biomarker for aMCI and AD. The FVEP-P2 has been shown to possess AD specific pathognomic information.

METHOD

A review was conducted of all articles published between the years 1976 and 2019 that examined the clinical utility of the FVEP-P2 in the diagnosis of aMCI or AD. Only 17 published investigations met the criteria of the review.

RESULT

The weighted average effect size, as measured by Cohen's d, was 1.07, with patients diagnosed with either aMCI or AD exhibiting a significant delay in the FVEP-P2 latency. The weighted mean latency for the controls was 143.92 ms (SD = 17.13). The weighted mean latency for the aMCI/AD was 164.02 ms (SD = 21.33). Estimates of sensitivity, specificity, and accuracy were based on the weighted means and standard deviations and were equal to 0.73. The area under the curve was equal to 0.78.

CONCLUSION

The results of the current review suggest that the FVEP-P2 latency possesses AD specific pathognomic information and that it should be included as part of a much larger assessment process that includes neuropsychological, cerebrospinal fluid, and brain imaging findings.

Brain Network Activation (BNA) reveals scopolamine-induced impairment of visual working memory

The overarching goal of this event-related potential (ERP) study was to examine the effects of scopolamine on the dynamics of brain network activation using a novel ERP network analysis method known as Brain Network Activation (BNA). BNA was used for extracting group-common stimulus-activated network patterns elicited to matching probe stimuli in the context of a delayed matching-to-sample task following placebo and scopolamine treatments administered to healthy participants. The BNA extracted networks revealed the existence of two pathophysiological mechanisms following scopolamine, disconnection, and compensation. Specifically, weaker frontal theta and parietal alpha coupling was accompanied with enhanced fronto-centro-parietal theta activation relative to placebo. In addition, using the characteristic BNA network of each treatment as well as corresponding literature-guided selective subnetworks as combined biomarkers managed to differentiate between individual responses to each of the treatments. Behavioral effects associated with scopolamine included delayed response time and impaired response accuracy. These results indicate that the BNA method is sensitive to the effects of scopolamine on working memory and that it may potentially enable diagnosis and treatment assessment of dysfunctions associated with cholinergic deficiency.

Effects of flash mode and intensity on P2 component latency and amplitude

Alzheimer's disease (AD) groups manifest flash visual-evoked potential (VEP) P2 component delays compared to healthy control groups. However, using P2 latency to categorize individual patients and controls yields low accuracy. Additionally, several laboratories have failed to replicate the basic between group P2 latency findings. The sporadic failure to find the P2 delay and, when found, its failure to classify patients and controls accurately may reflect the use of non-optimal stimuli or recording sites.

OBJECTIVE

This was a parametric investigation of stimulation and recording methods in healthy college students.

METHOD

Using an extended recording montage of 64 electrodes, 10 stimulus conditions (5 flash intensities through open and closed eyes) were evaluated for their P2 effects.

RESULT

The optimal recording site (O2) yielded the most reliable latencies and amplitudes across a range of stimulus intensities. Flash intensity did not affect P2 latency or amplitude. Flashes delivered through closed eyelids produced a flash VEP but delivery through open eyes produced a pattern VEP lacking a flash P2 component.

CONCLUSION

This accounts for the failure of some laboratories using open eyes to replicate the P2 delay in AD groups.

SIGNIFICANCE

Optimal flash VEP conditions include closed eyes and recording from O2. Flash intensity is unimportant.

Changes in the retinocortical evoked potentials in subjects 75 years of age and older

OBJECTIVE

Current trends are showing a rapid increase in the elderly population, particularly the subgroup that is 75 years of age or more. Considering the fact that several ocular diseases are more prevalent among the elderly, it is increasingly important to investigate normal visual function in this subgroup of our population. The objective of this study was to determine the effects of advanced aging on visual retinocortical function by evaluating the electrophysiological responses of the most rapidly increasing segment of the geriatric population.

METHODS

Fifty-eight healthy subjects between the ages of 20--32 years (n=30) and 75--88 years (n=28) participated in this study. We recorded their pattern electroretinograms (ERGs) and cortical visual evoked potentials (VEPs) under stimulus conditions biased toward the preferential response of the magnocellular and parvocellular subdivisions of the visual system.

RESULTS

Elderly subjects showed reduced ERG amplitudes relative to young participants. The amplitude of the VEPs also decreased with age, while their latency increased. The effect of senescence was most apparent under stimulus conditions combining the magnocellular and parvocellular pathway contributions and less pronounced when the stimulus conditions were biased to favor the response of either system.

CONCLUSIONS

Our results demonstrate that visual retinal and cortical function deteriorates with old age. Our data further indicate that senescence has widespread effects on the visual system, altering the functioning of both the magnocellular and parvocellular visual pathways.

Scopolamine reduces the P35m and P60m deflections of the human somatosensory evoked magnetic fields

Acetylcholine (ACh) is a potent neuromodulator in the brain with multiple, complex effects on neuronal function, most of which are mediated by muscarinic receptors. Generally, the most significant effect is excitation of pyramidal neurones and facilitation of responses to afferent stimulation. Much of the information on the ACh effects comes from studies utilizing in vitro or anesthetized in vivo preparations, while fewer data are available from awake animals or humans. We studied human somatosensory evoked magnetic fields (SEFs), which reflect summated postsynaptic currents in pyramidal neurones in area 3b, and in the opercular somatosensory cortex, when cholinergic transmission was modulated either by a central (scopolamine, 0.3 mg, i.v.) or peripheral (glycopyrrolate, 0.2 mg, i.v.) muscarinic antagonist. A randomized, double-blind, cross-over design was employed. SEFs were elicited by right median nerve stimulation at the wrist with constant-current pulses above motor threshold. The first excitatory cortical response from area 3b (N20m) was not affected by the central muscarinic blockade, while later P35m and P60m deflections were significantly reduced. The responses from the opercular somatosensory cortex showed some tendency toward reduction, but no significant alterations. The results show that somatosensory cortical processing can be modulated by muscarinic transmission at a relatively early stage. Relative membrane hyperpolarization of pyramidal neurons due to scopolamine (caused by blocking an ACh-induced tonic depolarization) is discussed as a possible mechanism underlying the observed effects.

Visual evoked responses in Alzheimer's disease: a review

This review of the literature has shown that a delayed flash P2, in the presence of a normal flash P1 and pattern-reversal P100, can distinguish groups of Alzheimer's patients from groups who are healthy, psychiatrically ill, or suffering from other types of dementia. The VER's usefulness in the individual patient remains undetermined. With today's techniques, too many patients are misclassified. False negatives may result if Alzheimer's patients with visual symptoms are a distinct subgroup. Those with a normal flash VER may have cortical dysfunction outside the visual association areas. This would most likely be in the earliest stages of the disease before the atrophy becomes widespread. It may be that a VER test would only be valid in established disease. Future research should use adequate numbers of patients who are in a single category of mild, moderate or severe, so that the applicability of a VER test in the early stages of the disease can be determined. Strict diagnostic criteria such as the NINCDS-ADRDA guidelines should be used. Patients should be drug free, or at least not taking medications with anticholinergic properties. Flash VER should be obtained using a strobe light with eyes closed, and the pattern VER using a black and white television with a large pattern and high contrast.